section name header

Pronunciation

is-RA-di-peen

Classifications

Therapeutic Classification: antianginals, antihypertensives

Pharmacologic Classification: calcium channel blockers

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed following oral administration but extensively metabolized, resulting in bioavailability.

Distribution: Unknown.

Protein Binding: 95%.

Metabolism/Excretion: Completely metabolized by the liver.

Half-life: 8 hr.

Time/Action Profile

(antihypertensive effects†)

ROUTEONSETPEAKDURATION
PO<2 hr2–3 hr12 hr

†For single doses, maximal antihypertensive effect during chronic dosing may take 2–4 wk.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: peripheral edema, HF, ARRHYTHMIAS, bradycardia, chest pain, hypotension, palpitations, syncope, tachycardia.

Derm: dermatitis, erythema multiforme, flushing, photosensitivity, pruritus/urticaria, rash, STEVENS-JOHNSON SYNDROME, sweating.

EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus.

Endo: gynecomastia, hyperglycemia.

GI: liver enzymes, anorexia, constipation, diarrhea, dry mouth, dyspepsia, nausea, vomiting.

GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency.

Hemat: anemia, leukopenia, thrombocytopenia.

Metab: weight.

MS: joint stiffness, muscle cramps.

Neuro: abnormal dreams, anxiety, confusion, dizziness, drowsiness, dysgeusia, headache, nervousness, paresthesia, psychiatric disturbances, tremor, weakness.

Resp: cough, dyspnea.
Misc: gingival hyperplasia.

Interactions

Drug-Drug:

Drug-Food:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

DynaCirc